January 15, 2026

Can Multimodal AI Models Predict Distant Recurrence Risk in Patients With Early Breast Cancer?

Multimodal artificial intelligence (AI) models using a combination of molecular, imaging, and clinical features improved the individual prognostic assessment of patients with early breast cancer's ris...

The ASCO Post

January 07, 2026

AI Enhances Detection of Missed Breast Cancers on Screening Tomosynthesis

A U.S. Food and Drug Administration (FDA)​​-cleared artificial intelligence (AI) algorithm was able to detect and correctly localize almost one-third of interval breast cancers in a retrospective eval...

The ASCO Post

January 06, 2026

AI Tops Density in Predicting Breast Cancer Risk

An image-only artificial intelligence (AI) model for predicting the 5-year risk of breast cancer provided stronger and more precise risk stratification than breast density assessment, according to a n...

The ASCO Post

January 02, 2026

Miami Cancer Institute Precision Oncology Symposium, Fourth Annual

This one-and-a-half-day symposium has been designed to provide an overview and opportunity to learn about the most recent advances in the treatment of solid tumors, including lung cancer, breast cancer, gastrointestinal tumors, genitourinary tumors, head and neck tumors, melanoma, sarcomas and brain tumors by novel targeted agents and treatment combinations.

Baptist Health South Florida

December 29, 2025

Revisiting Margin Width Guidelines for Ductal Carcinoma In Situ and the Role of Routine Reexcision

For postmenopausal women with HR-positive ductal carcinoma in situ (DCIS) treated with breast-conserving surgery, whole-breast irradiation, and adjuvant endocrine therapy, reexcision to achieve wider ...

The ASCO Post

October 01, 2025

Clinical Trials Unite Doctors, Researchers, and Patients to Advance Treatments

Evaluating new medical therapies in people through a rigorous, systematic process, known as a clinical trial, is the pinnacle of clinical research and the primary mechanism through which novel treatments are proven safe and effective in cancer — or any other disease.

Dana-Farber

December 15, 2025

Dana-Farber Research Supports FDA Approval of T-DXd Plus Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved trastuzumab deruxtecan (T-DXd) in combination with pertuzumab for first-line treatment of metastatic HER2-positive breast cancer.

Dana-Farber

March 10, 2023

Four Leading UPMC/Pitt Scientists Receive Funding for Research in Breast Cancer

UMPC Hillman Cancer Center researchers receive significant funding from the Breast Cancer Research Foundation to support investigations aiming to improve cancer screening and enhance HER2 therapy.

The ASCO Post

February 10, 2021

Severity of Patients’ Symptoms May Be Underrecognized During and After Breast Radiotherapy

Physicians may commonly underrecognize radiation-associated symptoms and their severity compared with self-reports of patients with breast cancer, according to a large study comparing patient-­reporte...

The ASCO Post